(Q46493763)

22 December 2017

title

Administration of a PPARalpha agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio (English)

1 reference

22 December 2017

author name string

Albert E Schultze

1

1 reference

22 December 2017

William E Alborn

2

1 reference

22 December 2017

Ronald K Newton

3

1 reference

22 December 2017

Robert J Konrad

4

1 reference

22 December 2017

publication date

16 May 2005

1 reference

22 December 2017

Journal of Lipid Research

published in

1 reference

22 December 2017

volume

46

1 reference

22 December 2017

issue

8

1 reference

22 December 2017

page(s)

1591-1595

1 reference

22 December 2017

The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?

cites work

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-α and Contains a Novel Farnesoid X-activated Receptor Response Element

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

Hyperlipidemia in patients with apolipoprotein E 2/2 phenotype: apolipoprotein A5 S19W mutation as a cofactor

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.C500010-JLR200

10.1194/JLR.C500010-JLR200

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

release_i5eobbz6y5batgkboxucihy7se

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/i5eobbz6y5batgkboxucihy7se

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

15897610

1 reference

22 December 2017